Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8TDQ7

UPID:
GNPI2_HUMAN

ALTERNATIVE NAMES:
Glucosamine-6-phosphate deaminase 2; Glucosamine-6-phosphate isomerase SB52

ALTERNATIVE UPACC:
Q8TDQ7; B4DJF3; Q2VYF1; Q59EA7; Q8NCZ8; Q96BJ4; Q96NC6

BACKGROUND:
The enzyme Glucosamine-6-phosphate isomerase 2, alternatively named Glucosamine-6-phosphate deaminase 2, is integral to the hexosamine biosynthetic pathway. It facilitates the reversible conversion of alpha-D-glucosamine 6-phosphate to beta-D-fructose 6-phosphate, a critical step in the synthesis of UDP-GlcNAc. This process is essential for the regulation of hyaluronan synthesis, which plays a significant role in tissue remodeling.

THERAPEUTIC SIGNIFICANCE:
The exploration of Glucosamine-6-phosphate isomerase 2's function offers a promising avenue for the development of novel therapeutic approaches. Given its central role in the synthesis of key biomolecules involved in tissue remodeling, targeting this enzyme could lead to breakthroughs in treating conditions associated with dysregulated tissue growth and repair.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.